Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

Assessment of fibroblast growth factor 23 in relation to peripheral arterial disease in type 2 diabetes mellitus

The Egyptian Journal of Internal Medicine volume 31, pages 902–907 (2019)Cite this article

Abstract

Background

Peripheral arterial disease (PAD) is a major vascular complication and the leading cause of amputation in people with diabetes. Fibroblast growth factor 23 (FGF-23) is a recently discovered 30-kD secreted hormone glycoprotein that plays a role in the complex and tightly regulated mechanisms of mineral metabolism. Increase in serum FGF-23 concentration was an independent predictor of coronary artery diseases in patients with mild chronic kidney disease and of mortality in patients undergoing hemodialysis. Recently, FGF-23 has been found to be associated with total body atherosclerosis and vascular dysfunction.

Objective

To evaluate the relation between FGF-23 and PAD in patients having type 2 diabetes with normal kidney function.

Patients and methods

A case-control study was conducted on 120 diabetic patients, where 60 patients having type 2 diabetes with PAD were compared with 60 patients having type 2 diabetes without PAD. All patients were subjected to full history taking, thorough clinical examination, ankle-brachial index assessment, and laboratory measurement of glycated hemoglobin%, estimated glomerular filtration rate, microalbuminuria, lipid profile, serum ionized calcium and phosphorous, and serum FGF-23.

Results

Significantly higher serum FGF-23 was found in diabetic patients with PAD compared with diabetic patients without PAD. Logistic regression analysis showed that duration of diabetes, triglycerides level, phosphorous level, glycated hemoglobin, and FGF-23 were independent predictors for PAD.

Conclusion

FGF-23 level was higher in type 2 diabetic patients with PAD, which highlights a possible implication of FGF-23 in the pathogenesis of PAD in type 2 diabetes.

References

  1. International Diabetes Federation (IDF). IDF diabetes atlas, 6th edition; 2013. Available at: www.diabetesatlas.org/component/attachments. [Accessed on 10 Jan 2019].

  2. Singh DK, Winocour P, Summerhayes B, Kaniyur S, Viljoen A, Sivakumar G, Farrington K. The foot in type 2 diabetes: is there link between vascularcalcification and bone mineral density?. Diabetes Res Clin Pract 2011; 94:410–416.

    Article  CAS  Google Scholar 

  3. Mukherjee D. Peripheral and cerebrovascular atherosclerotic disease in diabetes mellitus. Best Pract Res Clin Endocrinol Metab 2009; 23:335–345.

    Article  Google Scholar 

  4. Dalal M, Sun K, Cappola AR, Ferrucci L, Crasto C, Fried LP, Semba RD. Relationship of serum fibroblast growth factor 23 with cardiovascular disease in older community-dwelling women. Eur J Endocrinol 2011; 165:797–803.

    Article  CAS  Google Scholar 

  5. Kansal N, Hamdan A. Clinical features and diagnosis of macrovascular disease. The diabetic foot: medical and surgical management. New Jersey: Humana Press. 2002. 6:113–120.

    Google Scholar 

  6. Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, et al. American Heart Association Council on Peripheral Vascular Disease; Council on Epidemiology and Prevention; Council on Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association Circulation 2012; 126:2890–2909.

    PubMed  Google Scholar 

  7. Stang D. Target that risk: nationally agreed information and education leaflets for the diabetic. Diabetic Foot J 2008; 11:4.

    Google Scholar 

  8. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604–612.

    Article  Google Scholar 

  9. Weber TJ, Liu S, Indridason OS, Quarles LD. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 2003; 18:1227–1234.

    Article  CAS  Google Scholar 

  10. Conte MS, Pomposelli FB, Clair DG, Geraghty PJ, McKinsey JF, Mills JL, et al. Society for Vascular Surgery Lower Extremity Guidelines Writing Group. Society for vascular surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg 2015; 61:S2–S41.

    Google Scholar 

  11. Jüppner H. Phosphate and FGF-23. Kidney Int Suppl 2011; 79:S24–S27.

    Article  Google Scholar 

  12. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000; 277:494–498.

    Article  CAS  Google Scholar 

  13. Mehta R, Ying GS, Houston S, Isakova T, Nessel L, Ojo A. Fibroblast growth factor 23, the anklebrachialindex, and incident peripheral artery disease in the Cardiovascular Health Study. Atherosclerosis 2014; 233:91–96.

    Article  Google Scholar 

  14. Mirza MA, Larsson A, Melhus H, Linda L, Larsson TE. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009; 207:546–551.

    Article  CAS  Google Scholar 

  15. Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, Lorriaux C, et al. Peripheral vascular calcification in long haemodialysispatients: associated factors and survival consequences. Nephrol Dial Transpl 2009; 24:948–955.

    Article  CAS  Google Scholar 

  16. Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119:2545–2552.

    Article  Google Scholar 

  17. Hatipoğlu E, Özgür N, Niyazoğlu M. Impact of fibroblast growth factor-23 on peripheral arterial disease in type 2 diabetes mellitus: a comparative cross-sectional pilot study. Turk J Endocrinol Metab 2015; 19:119–123.

    Article  Google Scholar 

  18. Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (cardiovascular health study). J Am Coll Cardiol 2012; 60:200–207.

    Article  CAS  Google Scholar 

  19. Tavintharan S, Nang EK, Lim SC, Wu Y, Khoo CM, Lee J, et al. Prevalence and risk factors for peripheral artery disease in an Asian population with diabetes mellitus. DiabVasc Dis Res 2009; 6:80–86.

    Article  CAS  Google Scholar 

  20. Agarwal AK, Singh M, Arya V, Garg U, Singh VP, Jain V, et al. Prevalence of peripheral arterial disease in type 2 diabetes mellitus and its correlation with coronary artery disease and its risk factors. J Assoc Physicians India 2012; 60:28–32.

    CAS  PubMed  Google Scholar 

  21. Singh DK, Winocour P, Summerhayes B, Kaniyur S, Viljoen A, Sivakumar G, Farrington K. Prevalence and progression of peripheral vascular calcification intype 2 diabetes subjects with preserved kidney function. Diabetes Res Clin Pract 2012; 97:158–165.

    Article  CAS  Google Scholar 

  22. Al-Kaabi JM, Al Maskari F, Zoubeidi T, Abdulle A, Shah SM, Cragg P, et al. Peripheral artery disease in type 2 diabetes patients from the United Arab Emirates. J Diabetes Metab 2014; 5:388.

    Google Scholar 

  23. Al-Sheikh SO, Aljabri BA, Al-Ansary LA, Al Khayal LA, Al Salman MM, Al Omran MA. Prevalence of and risk factors for peripheral arterial disease in Saudi Arabia; Saudi Med J 2007; 28:412–414.

    PubMed  Google Scholar 

  24. Zitton RS, Khattab MS, Khalil KA, Hasb-Allah SA. Prevalence of peripheral arterial disease in diabetic patients attending in family medicine outpatient clinic in Suez Canal University Hospital. Med J Cairo Univ 2012; 80:25–29.

    Google Scholar 

  25. Jue LI, Buaijiaer HJ, Inming YU, et al. Prevalence of peripheral arterial disease and risk factors for low and high ankle brachial index in Chinese patients with type-2 diabetes. J Health Sci 2006; 52:97–102.

    Article  Google Scholar 

  26. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, et al. Independent association of low serum 25- hydroxyvitamin D and 1, 25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 2008; 168:1340–1349.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Endocrine and Metabolism, Ain Shams University, Abbassia Square, Ramsis Street, Cairo, 11591, Egypt

    Mohamed R. Halawa, Abeer A. Abdalah, Yara M. Eid, Merhan S. Nasr MD, Bassem M. Mostafa & Nesma H. Ahmed

Authors
  1. Mohamed R. Halawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abeer A. Abdalah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yara M. Eid
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Merhan S. Nasr MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bassem M. Mostafa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nesma H. Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Merhan S. Nasr MD.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Halawa, M.R., Abdalah, A.A., Eid, Y.M. et al. Assessment of fibroblast growth factor 23 in relation to peripheral arterial disease in type 2 diabetes mellitus. Egypt J Intern Med 31, 902–907 (2019). https://doi.org/10.4103/ejim.ejim_52_19

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_52_19

Keywords